Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 5, 2007, Pages 742-747

  Schelleman, H ^a   Chen, Z ^a   Kealey, C ^a   Whitehead, A S ^a   Christie, J ^a   Price, M ^a   Brensinger, C M ^a   Newcomb, C W ^a   Thorn, C F ^a   Samaha, F F ^a   Kimmel, S E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AFRICAN AMERICANS; AGED; ANTICOAGULANTS; APOLIPOPROTEINS E; ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; CONFIDENCE INTERVALS; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; ODDS RATIO; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WARFARIN;

EID: 34247215617     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100144     Document Type: Article

References (22)

1. Breckenridge, A.M. Interindividual differences in the response to oral anticoagulants. Drugs 14, 367-375 (1977).
2. Hirsh, J. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119(Suppl 1): 8S-21S (2001).
3. Dang, M.T., Hambleton, J. & Kayser, S.R. The influence of ethnicity on warfarin dosage requirement. Ann. Pharmacother. 39, 1008-1012 (2005).
4. Cain, D., Hutson, S.M. & Wallin, R. Assembly of the warfarin-sensitive vitamin K 2, 3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J. Biol. Chem. 272, 29068-29075 (1997).
5. D'Andrea, G. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
6. Rieder, M.J. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
7. Veenstra, D.L. et al. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15, 687-691 (2005).
8. Wadelius, M. et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
9. Herman, D., Peternel, P., Stegnar, M., Breskvar, K. & Dolzan, V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb. Haemost. 95, 782-787 (2006).
10. Lee, S.C. et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79, 197-205 (2006).
11. Li, T. et al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J. Med. Genet. 43, 740-744 (2006).
12. Obayashi, K. et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther. 80, 169-178 (2006).]
13. Osman, A., Enstrom, C., Arbring, K., Soderkvist, P. & Lindahl, T.L. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J. Thromb. Haemost. 4, 1723-1729 (2006).
14. Takahashi, H. et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110 (2006).
15. Schalekamp, T. et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther. 80, 13-22 (2006).
16. Geisen, C. et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94, 773-779 (2005).
17. Moll, S. & Ortel, T.L. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann. Intern. Med. 127, 177-185 (1997).
18. Richards, B. et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum. Mol. Genet. 2, 159-163 (1993).
19. Kealey, C. et al. Warfarin and CYP2C9 genotype-evidence for ethnic variation in warfarin sensitivity. Thromb. Haemost., (submitted).
20. Nasu, K., Kubota, T. & Ishizaki, T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7, 405-409 (1997).
21. Box, G.E.P. & Cox, D.R. An analysis of transformations. J. Roy. Stat. Soc. Series B 26, 211-252 (1964).
22. Draper, N.R. Applied Regression Analysis. 2nd edn. (John Wiley & Sons, New York, 1981).